Yıldız İ, Özer L, Şenocak Taşçı E, Bayoglu İV, Aytac E. Current trends in perioperative treatment of resectable gastric cancer. World J Gastrointest Surg 2023; 15(3): 323-337 [PMID: 37032791 DOI: 10.4240/wjgs.v15.i3.323]
Corresponding Author of This Article
Leyla Özer, MD, Associate Professor, Department of Medical Oncology, Acıbadem MAA University, Halkalı Merkez, Turgut Özal Bulvarı No:16, Küçükçekmece/ İstanbul, İstanbul 34567, Turkey. leyla.ozer@acibadem.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Mar 27, 2023; 15(3): 323-337 Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.323
Current trends in perioperative treatment of resectable gastric cancer
İbrahim Yıldız, Leyla Özer, Elif Şenocak Taşçı, İbrahim Vedat Bayoglu, Erman Aytac
İbrahim Yıldız, Leyla Özer, Department of Medical Oncology, Acıbadem MAA University, İstanbul 34567, Turkey
Elif Şenocak Taşçı, Department of Medical Oncology, Acıbadem University, İstanbul 34567, Turkey
İbrahim Vedat Bayoglu, Department of Medical Oncology, Marmara University, İstanbul 12345, Turkey
Erman Aytac, Department of Surgery, Acibadem University School of Medicine, Istanbul 34567, Turkey
Author contributions: Yıldız İ wrote the paper; Özer L, Şenocak Taşçı E and Aytac E collected the data; Bayoglu İV prepared the figure and tables.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Leyla Özer, MD, Associate Professor, Department of Medical Oncology, Acıbadem MAA University, Halkalı Merkez, Turgut Özal Bulvarı No:16, Küçükçekmece/ İstanbul, İstanbul 34567, Turkey. leyla.ozer@acibadem.com
Received: October 28, 2022 Peer-review started: October 28, 2022 First decision: November 30, 2022 Revised: January 5, 2023 Accepted: February 27, 2023 Article in press: February 27, 2023 Published online: March 27, 2023
Abstract
In the last few decades, the treatment strategy for locally advanced resectable gastric cancer (GC) has shifted to a multimodal approach, which potentially decreases recurrence risk and improves survival rates. Perioperative therapy leads to downstaging, increased curative resection rates, and prolonged disease-free and overall survival, by preventing micrometastases in patients with resectable GC. Application of neoadjuvant therapy provides information about tumor biology and in vivo sensitivity. A consensus regarding the therapeutic approach for non-metastatic GC does not exist, and many clinical trials aim to clarify this aspect. Advances in precision medicine and the role of immunotherapy have been the focus of research in GC treatment. Herein, the current status and possible future developments of perioperative therapy for locally advanced resectable GC are reviewed, based on the most recent randomized clinical trials.
Core Tip: The results of the most recent randomized studies have led to a shift from traditional care concepts towards evidence-based multimodal treatment strategies for gastric cancer (GC). Perioperative chemotherapy has become the standard of care for resectable GC. Molecular-based modifications of the backbone treatment increase the efficacy of therapy.
